- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.12.25 | Stocks to buy in 2026: SAI Life, Varun Beverages among 5 stocks that could give 11-40% return in 1 year | 1 | Times of India | ||
| 19.12.25 | SAI LIFE SCIENCES LIMITED: Sai Life Sciences Releases Sustainability Report 2024-25 | 607 | GlobeNewswire (Europe) | HYDERABAD, India, Dec. 19, 2025, today announced the release of its Sustainability Report for 2024-25. Aligned with the Global Reporting Initiative.
Commenting on the release, Krishna Kanumuri,... ► Artikel lesen | |
| 28.10.25 | Sai Life Sciences verdoppelt FuE-Kapazitäten mit neuer Anlage in Hyderabad | 461 | Business Wire | Sai Life Sciences Limited (BSE: 544306 NSE: SAILIFE), eines der am schnellsten wachsenden Auftragsforschungs-, Entwicklungs- und Produktionsunternehmen (CRDMO) Indiens, meldete heute den Spatenstich... ► Artikel lesen | |
| SAI LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 27.10.25 | Sai Life Sciences Set to Double Process R&D Capacity With New Facility in Hyderabad | 299 | Business Wire | Sai Life Sciences Limited (BSE: 544306 NSE: SAILIFE), one of India's fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO), today announced the groundbreaking for... ► Artikel lesen | |
| 08.10.25 | SAI LIFE SCIENCES LIMITED: Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announce an 'Integrated CMC Partnership' to accelerate drug development for innovators | 313 | GlobeNewswire (Europe) | MANCHESTER, United Kingdom and HYDERABAD, India, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), Agility Life Sciences, and Centrix Pharma Solutions today announced... ► Artikel lesen | |
| 19.09.25 | Stock Alert: Senores Pharma, Ramky Infra, Thomas Cook, Sai Life Sciences | 1 | capitalmarket.com | ||
| 19.09.25 | Sai Life Sciences eröffnet spezielle Anlage für veterinärmedizinische Wirkstoffe in Bidar, Indien | 447 | Business Wire | Sai Life Sciences (BSE: 544306 NSE: SAILIFE), ein auf Innovatoren ausgerichtetes Auftragsforschungs-, Entwicklungs- und Produktionsunternehmen (CRDMO), gab heute die Eröffnung von Unit VI bekannt... ► Artikel lesen | |
| 18.09.25 | Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India | 348 | Business Wire | Sai Life Sciences (BSE: 544306 NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility... ► Artikel lesen | |
| 28.08.25 | SAI LIFE SCIENCES LIMITED: Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL | 400 | GlobeNewswire (Europe) | HYDERABAD, India, Aug. 28, 2025, today announced the completion of Phase II of its new Production Block (PB-11) at the company's flagship API manufacturing facility in Bidar, India (Unit IV).
The... ► Artikel lesen | |
| 26.08.25 | Sai Life Sciences slips as block deal sparks talk of TPG Asia exit | 1 | capitalmarket.com | ||
| 26.08.25 | Volumes spurt at Sai Life Sciences Ltd counter | 1 | capitalmarket.com | ||
| 20.08.25 | SAI LIFE SCIENCES LIMITED: Sai Life Sciences secures SBTi validation for near-term climate targets | 462 | GlobeNewswire (Europe) | HYDERABAD, India, Aug. 20, 2025, announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)-a corporate climate action... ► Artikel lesen | |
| 12.08.25 | Concord Biotech, Sai Life Sciences among 9 stocks that closed above VWAP on August 11 | 1 | Times of India | ||
| 11.08.25 | Jefferies stuft Sai Life Sciences hoch: Expansionspläne als Wachstumstreiber | 2 | Investing.com Deutsch | ||
| 11.08.25 | Sai Life Sciences stock rating upgraded to Buy at Jefferies on capacity expansion plans | 3 | Investing.com | ||
| 10.08.25 | Breakout Stocks: Sai Life Sciences, Global Health and TVS Motor hit fresh 52-week highs; how to trade now | 2 | Times of India | ||
| 08.08.25 | Sai Life Sciences Limited Reports Revenue growth of 77% YoY | 226 | GlobeNewswire (Europe) | HYDERABAD, India, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused, Contract Research, Development and Manufacturing Organization (CRDMO)... ► Artikel lesen | |
| 03.04.25 | SAI LIFE SCIENCES LIMITED: Sai Life Sciences sets up Peptide Research Center in India | 559 | GlobeNewswire (Europe) | HYDERABAD, India, April 03, 2025, has inaugurated a dedicated Peptide Research Center at its integrated R&D Campus in Hyderabad, India.
Announcing the launch, Krishna Kanumuri, CEO & Managing... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HARROW | 49,000 | 0,00 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 6,450 | +1,10 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Broadens Patent Estate for Anaphylm | New patents extend protection for Anaphylm into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe... ► Artikel lesen | |
| LB PHARMACEUTICALS | 22,250 | +3,49 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer | NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 16,910 | +0,71 % | Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) | - NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 78,26 | +3,18 % | H.C. Wainwright reiterates Buy rating on Bright Minds stock with $115 target | ||
| MILESTONE PHARMACEUTICALS | 2,020 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables... ► Artikel lesen | |
| LIPOCINE | 8,030 | +22,22 % | Lipocine Inc.: Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone | Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026
Topline results on track for the second quarter of 2026
SALT LAKE CITY... ► Artikel lesen | |
| INTERCURE | 0,910 | -8,36 % | Intercure Ltd. - 6-K, Report of foreign issuer | ||
| INHIBIKASE THERAPEUTICS | 2,050 | +4,06 % | Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path | ||
| JOURNEY MEDICAL | 7,710 | +1,18 % | Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | Third quarter 2025 net revenues were $17.6 million Emrosi total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 5,650 | 0,00 % | NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards | EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American's... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 6,770 | 0,00 % | Kazia Therapeutics Limited: Kazia Therapeutics Regains Full Nasdaq Listing Compliance | Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength
SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 0,279 | +0,36 % | Reviva Pharmaceuticals: Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum | ||
| OMNIAB | 1,840 | -1,08 % | OmniAb outlines $18M-$22M 2025 revenue guidance while launching OmniUltra and expanding xPloration platform | ||
| VYNE THERAPEUTICS | 0,579 | +2,79 % | VYNE Therapeutics: +167% für den NBC! | Kurz vor Weihnachten ist schon wieder Bescherung im No Brainer Club: VYNE Therapeutics liefert nach einem Top-Deal satte +167% Rendite innerhalb weniger Monate. Die Weihnachtsgeschenke der NBC-Mitglieder... ► Artikel lesen |
SAI LIFE SCIENCES LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SAI LIFE SCIENCES LTD finden Sie auf Wallstreet Online.